- Home
- LIDR vs MTVA Comparison
LIDR vs MTVA Comparison
Compare LIDR & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- MTVA
- Stock Information
- Founded
- LIDR 2013
- MTVA 2014
- Country
- LIDR United States
- MTVA United States
- Employees
- LIDR N/A
- MTVA N/A
- Industry
- LIDR Auto Parts:O.E.M.
- MTVA
- Sector
- LIDR Consumer Discretionary
- MTVA
- Exchange
- LIDR Nasdaq
- MTVA NYSE
- Market Cap
- LIDR 14.8M
- MTVA 14.3M
- IPO Year
- LIDR N/A
- MTVA N/A
- Fundamental
- Price
- LIDR $0.92
- MTVA $0.66
- Analyst Decision
- LIDR Hold
- MTVA Strong Buy
- Analyst Count
- LIDR 1
- MTVA 2
- Target Price
- LIDR N/A
- MTVA $7.50
- AVG Volume (30 Days)
- LIDR 577.6K
- MTVA 142.2K
- Earning Date
- LIDR 08-04-2025
- MTVA 08-13-2025
- Dividend Yield
- LIDR N/A
- MTVA N/A
- EPS Growth
- LIDR N/A
- MTVA N/A
- EPS
- LIDR N/A
- MTVA N/A
- Revenue
- LIDR $246,000.00
- MTVA N/A
- Revenue This Year
- LIDR $2,677.23
- MTVA N/A
- Revenue Next Year
- LIDR $409.09
- MTVA N/A
- P/E Ratio
- LIDR N/A
- MTVA N/A
- Revenue Growth
- LIDR N/A
- MTVA N/A
- 52 Week Low
- LIDR $0.49
- MTVA $0.63
- 52 Week High
- LIDR $4.30
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- LIDR 65.47
- MTVA N/A
- Support Level
- LIDR $0.71
- MTVA N/A
- Resistance Level
- LIDR $0.88
- MTVA N/A
- Average True Range (ATR)
- LIDR 0.09
- MTVA 0.00
- MACD
- LIDR 0.00
- MTVA 0.00
- Stochastic Oscillator
- LIDR 89.21
- MTVA 0.00
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.